Eurazeo joins Excelya to fund European clinical research scale-up

Eurazeo has taken the lead in a new financing round for clinical research organisation Excelya, providing the backing the group says it needs to accelerate European expansion and technology investment. The operation combines equity from Eurazeo’s Flex Financing team with a structured bank facility coordinated by Banque Populaire Val de France and Banque Populaire Rives de Paris, with participation from BNP Paribas, Crédit Lyonnais and Société Générale.

Founded in 2014 by François Moisson and Frédéric Paqueville, Excelya has built a pan‑European footprint as a contract research organisation (CRO). The firm reports having supported more than 550 clinical studies across oncology, haematology, rare and paediatric disorders, infectious disease, immunotherapy and real‑world evidence (RWE) programmes. Management says the new capital will fund targeted acquisitions and scaling of digital capabilities.

The transaction also includes a leadership transition: founder Frédéric Paqueville will move away from daily operational duties, leaving a management team working alongside François Moisson to drive the next phase of growth. Eurazeo’s Flex Financing unit is known for tailoring equity and quasi‑equity structures that let founders or families retain control while providing growth capital and governance support.

From a market perspective, Europe’s CRO sector has been consolidating as mid‑market specialist providers pursue scale to meet rising demand for decentralised trials, RWE and AI‑enabled data processing. Industry estimates put the global outsourced clinical trials market at tens of billions of dollars with mid‑single digit annual growth; in this context, scale and digital differentiation can be decisive for winning mandates from mid‑sized pharma and biotech clients.

Excelya plans to channel part of the investment into automation and artificial intelligence tools to improve data quality and operational efficiency during trial execution. Management argues that these capabilities reduce timelines and costs for sponsors while improving patient monitoring and data integrity — attributes increasingly prized by pharmaceutical companies seeking to shorten development cycles.

Valérie Ducourty, Managing Director at Eurazeo – Flex Financing, said the investment fits the firm’s strategy of backing European companies that combine strong technical expertise with clear societal impact. The firm highlights healthcare sovereignty and the need for resilient, Europe‑based clinical development capacity as strategic drivers for the deal.

For Excelya, the alliance with Eurazeo and the bank syndicate is intended to create a platform capable of consolidating complementary CRO assets and delivering end‑to‑end services to mid‑market sponsors. François Moisson described the move as a step to accelerate growth across Europe while maintaining the company’s stated purpose of advancing new ways to heal. Market watchers say the deal underlines continued investor appetite for specialised service providers that can combine scientific depth with digital transformation.